Alfred E Chang
Overview
Explore the profile of Alfred E Chang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
3150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng F, Zhang S, Chang A, Moon J, Wicha M, Wang S, et al.
Int J Biol Sci
. 2025 Feb;
21(4):1819-1836.
PMID: 39990669
Cancer stem cell (CSC)-targeted immunotherapy has emerged as a novel strategy in cancer treatment in the past decade. However, its efficacy is significantly limited due to the existence of host...
2.
Aikins M, Qin Y, Dobson H, Najafabadi A, Lyu K, Xu Y, et al.
J Control Release
. 2022 Oct;
351:872-882.
PMID: 36206945
One of the major reasons for poor cancer outcomes is the existence of cancer stem cells (CSCs). CSCs are a small subpopulation of tumor cells that can self-renew, differentiate into...
3.
Thompson J, Sinco B, McCaffrey R, Chang A, Sabel M, Dossett L, et al.
J Surg Oncol
. 2022 Sep;
127(1):18-27.
PMID: 36069388
Background: Sentinel node biopsy (SLNB) is not routinely recommended for patients undergoing prophylactic mastectomy (PM), yet omission remains a subject of debate among surgeons. A modern patient cohort was examined...
4.
Qin Y, Lu F, Lyu K, Chang A, Li Q
Front Immunol
. 2022 Aug;
13:881427.
PMID: 35967441
Controversial views regarding the roles of B cells in tumor immunity have existed for several decades. However, more recent studies have focused on its positive properties in antitumor immunity. Many...
5.
Liao F, Zhang J, Hu Y, Najafabadi A, Moon J, Wicha M, et al.
Cancer Immunol Immunother
. 2022 Jan;
71(8):1959-1973.
PMID: 35098344
Cancer immunotherapies may be limited by their failure to target cancer stem cells (CSCs). We previously described an approach to target these cells using a dendritic cell (DC) vaccine primed...
6.
Dobson H, Ruan S, Chang A, Wicha M, Li Q
Oncotarget
. 2021 Sep;
12(18):1850-1858.
PMID: 34504657
Integrins mediate cell-cell interactions and communication with the extracellular matrix (ECM). These transmembrane protein receptors allow binding between a cell and its surroundings, initiating a breadth of intracellular signaling resulting...
7.
Oba T, Makino K, Kajihara R, Yokoi T, Araki R, Abe M, et al.
J Immunother Cancer
. 2021 May;
9(5).
PMID: 34049930
Background: Dendritic cells (DCs) are a promising therapeutic target in cancer immunotherapy given their ability to prime antigen-specific T cells, and initiate antitumor immune response. A major obstacle for DC-based...
8.
Xia L, Wen L, Qin Y, Dobson H, Zhang T, Comer F, et al.
Cell Chem Biol
. 2021 Mar;
28(5):610-624.e5.
PMID: 33711257
We previously tested HER2-targeted antibody-drug conjugates (ADCs) in immunocompromised (SCID) mice, precluding evaluation of host immunity, impact on cancer stem cells (CSCs), and potential benefit when combined with PD-L1 blockade....
9.
Ng S, Sabel M, Hughes T, Chang A, Dossett L, Jeruss J
J Surg Res
. 2021 Jan;
261:67-73.
PMID: 33421795
Background: The management of clinically node-positive breast cancer after neoadjuvant chemotherapy (NAC) has progressed with the potential to avoid the morbidity of axillary lymph node dissection in patients with complete...
10.
Najafabadi A, Zhang J, Aikins M, Abadi Z, Liao F, Qin Y, et al.
Nano Lett
. 2020 Sep;
20(10):7783-7792.
PMID: 32926633
Cancer stem cells (CSCs) proliferate extensively and drive tumor metastasis and recurrence. CSCs have been identified in over 20 cancer types to date, but it remains unknown how to target...